📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 22:34
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
34 announcements match the current filters (relevance ≥ 5).
RPGLife restructuring API unit: ₹243.33 Cr PE raise from InvAscent, ₹215 Cr acquisitions
RPG Life Sciences announced the subsidiarization of its API business into RPG Active Pharma (RPGAP), in which PE firm InvAscent is investing ~₹243.33 Cr for a 40% stake (leaving RPGLife with 60%). RPGAP is simultaneously executing two strategic acquisitions totaling ~₹215 Cr: Actis Generics for ~₹80 Cr and Raghava Life Sciences for ~₹135 Cr. The acquisitions expand installed API capacity by 4x (adding 300 KL capacity at Raghava with ~₹200 Cr revenue potential), creating an integrated API platform alongside FY26 external API sales of ~₹95.1 Cr.
Confidence: HIGH
What changedRPGLife has carved out its API business into RPGAP, brought in InvAscent as a 40% equity partner for ₹243.33 Cr, and funded two API acquisitions (Actis Generics and Raghava Life Sciences) worth ~₹215 Cr.
Why it mattersThis transforms RPGLife's niche API arm into a scaled, backward-integrated 4x capacity platform with dedicated PE growth capital, reducing reliance on core formulations without straining parent debt.
InvAscent primary investment: ₹243.33 CrInvAscent diluted stake: 40%Actis Generics consideration: ₹80 CrRaghava Life Sciences consideration: ₹135 CrRaghava revenue potential: ₹200 CrAcquisitions vs TTM revenue: ~29.3%
📅 Short termPositive sentiment likely driven by value unlocking in the API division, growth capital infusion, and immediate platform scaling without balance sheet dilution at the parent level.
📈 Long termSignificantly strengthens RPGLife's overall pharma ecosystem by creating an independent, well-capitalized API player with 300+ KL capacity, WHO/EU GMP compliance, and cross-selling synergies.
⚠ Risk flags
- Integration execution risks across two simultaneous acquisitions (Actis and Raghava)
- Subject to final transaction closing conditions specified in agreements dated July 29 and September 2, 2026
Key Highlights
InvAscent investing ~₹243.33 Cr for a 40% primary equity stake in newly subsidiarized API entity RPGAP.
RPGAP acquiring 100% of Actis Generics for ~₹80 Cr (incl. NWC) to add Anti-Diabetic and Cardiology API portfolios.
RPGAP acquiring Raghava Life Sciences via slump sale for ~₹135 Cr, adding 300 KL capacity with ~₹200 Cr revenue potential.
Total combined acquisition outlay of ~₹215 Cr represents ~29.3% of RPGLife's TTM revenue of ₹735 Cr.
API unit had FY26 external third-party sales of ~95.1 Cr INR prior to the carve-out.
👀 What to Watch
Track the closing of the definitive agreements dated July 29, 2026 and September 2, 2026, alongside margin accretion and synergy execution in the API segment over the next 2-4 quarters.
RPG Active Pharma acquires Raghava Life Sciences' API business for up to ₹135 cr
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences for up to ₹135 crore on a slump-sale basis. The acquisition adds an EU-GMP and WHO-GMP approved facility near Hyderabad with ~300 KL installed capacity across 9 acres. The transaction brings a portfolio of 22 commercialized APIs and 7 development-stage molecules across cardiovascular, diabetes, and CNS segments. At up to ₹135 crore, the deal value represents ~18.4% of RPG Life Sciences' TTM revenue (₹735 crore) and ~22.3% of its net worth (₹605 crore).
Confidence: HIGH
What changedRPG Life Sciences' subsidiary executed a Business Transfer Agreement to acquire the API business of Raghava Life Sciences for up to ₹135 crore.
Why it mattersThe deal substantially bolsters RPG's API manufacturing footprint (+300 KL capacity) and product pipeline, driving backward integration and export market expansion alongside its prior Actis Generics buyout.
Acquisition consideration: up to ₹135 croreDeal value vs TTM revenue: ~18.4%Deal value vs Net worth: ~22.3%Capacity added: ~300 KLProduct additions: 22 commercialized + 7 pipeline APIs
📅 Short termPositive for market sentiment as the company deploys capital into inorganic scale expansion; monitor customary closing milestones.
📈 Long termStructurally scales the API division by integrating 300 KL capacity, widening therapy access, and creating operational synergies with Actis Generics over coming quarters.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration and capacity utilization ramp-up risks
- Subject to regulatory approvals and customary closing conditions
Key Highlights
Acquisition of API and intermediates business undertaking for up to ₹135 crore via slump sale
Adds ~300 KL installed capacity across a 9-acre EU-GMP/WHO-GMP approved facility near Hyderabad
Expands portfolio with 22 commercialized APIs and 7 development-stage assets across diabetes, CNS, and cardiovascular therapies
Secures international regulatory credentials including CEP, EU Written Confirmation, and KDMF approvals
👀 What to Watch
Track the completion of closing conditions, regulatory clearances, and the timeline for operational and financial integration in upcoming quarterly disclosures.
RPGLIFE Unit to Acquire Raghava Life Sciences API Business for up to ₹135 Cr
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited, has executed a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (APIs) and intermediates business of Raghava Life Sciences for up to ₹135 crore in cash. The acquired undertaking reported unaudited revenues of approximately ₹19 crore in FY26 and includes manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules (22 commercialized and 7 in development). The transaction represents ~22.3% of RPG Life's net worth (₹605 crore) and is expected to close within 30 days subject to closing conditions and regulatory approvals.
Confidence: HIGH
What changedRPG Life Sciences has agreed to acquire the API and intermediates business undertaking of Raghava Life Sciences on a slump sale basis through its wholly owned subsidiary.
Why it mattersThe deal expands RPG Life's active pharmaceutical ingredient (API) manufacturing and R&D footprint while adding 29 molecules to strengthen backward integration and product offerings.
Acquisition consideration: up to ₹135 croresDeal size vs Net Worth: ~22.3%Target FY26 revenue: about ₹19 CroresAPI molecules acquired: 29 (22 commercialized, 7 under development)Expected timeline: within 30 days
📅 Short termPositive sentiment from strategic inorganic growth; monitoring transaction closure and any cash outlay impact on the balance sheet.
📈 Long termStrengthens RPG Life's API capability and captive pipeline through 29 molecules and added R&D infrastructure, supporting long-term margin resilience.
⚠ Risk flags
- High acquisition price relative to the target's current revenue (~7.1x FY26 revenue)
- Execution and integration risks of new manufacturing and R&D facilities
Key Highlights
Acquisition of API and intermediates business via slump sale for a cash consideration of up to ₹135 crore
Target business generated ~₹19 crore revenue in FY26 (unaudited)
Includes manufacturing and R&D facilities plus 29 API molecules (22 commercialized, 7 under development)
Expected completion tentatively within 30 days, subject to closing conditions and regulatory approvals
👀 What to Watch
Track the completion timeline within the 30-day window and management commentary in upcoming quarterly updates regarding integration costs and capacity utilization.
RPG Life to Acquire Raghava's API Business for up to ₹135 Cr via Slump Sale
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited, has approved a Business Transfer Agreement to acquire the API and Intermediates business of Raghava Life Sciences for up to ₹135 crore in cash. The acquired business undertaking generated approximately ₹19 crore in revenue during FY26 and includes manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules (22 commercialized and 7 under development). The deal consideration represents approximately 22.3% of RPG Life's net worth (₹605 crore) and 18.4% of TTM revenue (₹735 crore). The transaction is slated to close within 30 days, subject to closing conditions and local regulatory approvals.
Confidence: HIGH
What changedRPG Life Sciences is acquiring Raghava Life Sciences' API and intermediates business, including plants, R&D, and 29 molecules, for up to ₹135 crore.
Why it mattersThe acquisition significantly expands RPG Life's API manufacturing footprint, pipeline (adding 29 molecules), and in-house R&D capabilities, accelerating its API expansion strategy.
Acquisition Consideration: up to ₹135 croreTarget FY26 Revenue: about ₹19 croreAPI Molecules Acquired: 29 molecules (22 commercialized, 7 under development)Consideration vs Net Worth: ~22.3%Target Revenue vs TTM Revenue: ~2.6%
📅 Short termDeal closure is expected within ~30 days with no immediate material EPS dilution given RPG's strong balance sheet (D/E of 0.03).
📈 Long termEnhances backward integration and API product offerings across domestic and export markets, supporting the company's long-term growth target.
⚠ Risk flags
- Integration risk of newly acquired manufacturing assets and R&D facilities
- Relatively high deal valuation relative to current target sales (~7.1x FY26 revenue), requiring strong operational ramp-up
Key Highlights
Total cash consideration of up to ₹135 crore for the API and intermediates business via slump sale
Acquiring business generated ~₹19 crore in revenue in FY26 (unaudited)
Includes manufacturing facilities, an R&D facility, and a portfolio of 29 API molecules (22 commercialized, 7 under development)
Expected deal completion within tentatively 30 days
👀 What to Watch
Track the completion of closing conditions within the 30-day window and monitor subsequent quarterly updates on the integration and capacity utilization of the acquired API manufacturing assets.
RPG Life Sciences Invests ₹65.69 Cr in Subsidiary RPG Active Pharma
RPG Life Sciences Limited has invested ₹65.69 Cr by subscribing to a rights issue of 21,89,535 equity shares of its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP). Following this allotment on August 14, 2026, the company maintains 100% ownership in RPGAP. The subsidiary, incorporated on December 24, 2025, has not yet commenced commercial operations and has reported zero turnover to date. The investment represents approximately 10.9% of RPGLIFE's net worth of ₹605 Cr and supports the operationalization of its dedicated API business structure.
Confidence: HIGH
What changedRPG Life Sciences completed an equity infusion of ₹65.69 Cr into its 100% subsidiary RPG Active Pharma Limited via a rights issue.
Why it mattersProvides dedicated equity capitalization (equating to ~10.9% of RPGLIFE net worth) to operationalize and structure its API business vertical.
Investment Amount: ₹65.69 CrShares Allotted: 21,89,535Investment vs Net Worth: ~10.9%Allotment Date: August 14, 2026Post-issue Holding: 100%
📅 Short termLimited near-term financial impact on consolidated performance as this is an internal capital allocation to a 100% owned entity.
📈 Long termSeparating or scaling API operations via a dedicated subsidiary may improve operational focus and regulatory agility across formulations and bulk drugs.
⚠ Risk flags
- Operational execution and commercialization timeline risks for the new subsidiary
Key Highlights
Subscribed to rights issue of RPG Active Pharma Limited for a total cash consideration of ₹65,68,60,500 (₹65.69 Cr).
Allotted 21,89,535 equity shares of face value ₹10 each on August 14, 2026.
Shareholding in RPG Active Pharma Limited remains 100% post-allotment.
RPG Active Pharma was incorporated on December 24, 2025, and is yet to commence commercial operations.
👀 What to Watch
Monitor upcoming quarterly updates regarding the operationalization and timeline of the API business transfer into RPG Active Pharma.
RPGLIFE to Invest ₹65.69 Cr in Wholly Owned Subsidiary RPG Active Pharma via Rights Issue
RPG Life Sciences Limited has invested up to ₹65.69 crore by subscribing to a rights issue of 21,89,535 equity shares in its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP). Incorporated in December 2025, RPGAP is yet to commence operations and has zero turnover to date. Following this cash subscription allotted on August 14, 2026, RPGLIFE retains 100% shareholding in the entity. The investment represents approximately 10.9% of RPGLIFE's net worth of ₹605 crore.
Confidence: HIGH
What changedRPGLIFE committed ₹65.69 crore in fresh cash equity into its pre-operational API subsidiary, RPG Active Pharma Limited.
Why it mattersProvides required capital to operationalize its dedicated Active Pharmaceutical Ingredient (API) subsidiary, aligning with long-term backward integration and capacity expansion strategies.
Investment Amount: Rs. 65,68,60,500Shares Allotted: 21,89,535 sharesPost-issue Holding: 100%Investment vs Net Worth: ~10.9%Target Turnover: Rs. 0 (pre-operational)
📅 Short termNeutral immediate impact on earnings as the cash outflow is an internal group investment into a non-operational entity.
📈 Long termSupports strategic scaling and potential dedicated focus on bulk drug/API manufacturing once the subsidiary establishes commercial operations.
⚠ Risk flags
- Project execution and gestation risks associated with a newly incorporated subsidiary yet to commence commercial operations.
Key Highlights
Equity infusion of up to ₹65.69 crore in wholly owned subsidiary RPG Active Pharma Limited
Allotment of 21,89,535 equity shares of face value ₹10 each completed on August 14, 2026
RPG Life Sciences retains 100% equity holding post-rights issue
RPGAP was incorporated on December 24, 2025, and has not yet commenced commercial operations
👀 What to Watch
Track subsequent disclosures on RPGAP's operational commencement, plant setup/capex timelines, and expected commercial API production dates.
₹700 Cr API Initiative: RPG Life Sciences to Spin-off API Unit and Acquire Actis Generics
RPG Life Sciences is restructuring its API business by transferring it to a wholly-owned subsidiary, RPG Active Pharma (RPGAP), via a slump sale. To accelerate growth, healthcare PE firm InvAscent will invest an initial ₹243 crore, with a total investment roadmap of up to ₹700 crore planned between the parent and the PE firm. Additionally, RPGAP will acquire 100% of Actis Generics, an API manufacturer in Visakhapatnam, to expand its manufacturing base. This strategic move aims to decouple the API and formulations businesses for better management focus and capital allocation.
Confidence: HIGH
What changedThe company is carving out its API division into a separate subsidiary with external PE funding and an immediate inorganic acquisition.
Why it mattersThis represents a massive scale-up effort; the ₹700 crore investment plan nearly matches the company's current annual revenue, signaling a major shift toward becoming a significant API player alongside its formulations business.
Initial PE Investment: ₹243 croreTotal Investment Roadmap: ₹700 croreInvestment vs TTM Revenue: ~98.8%Actis Generics Acquisition: 100% equityTTM Revenue: ₹708 crore
📅 Short termThe market is likely to react positively to the PE validation and the aggressive growth roadmap involving both organic and inorganic expansion.
📈 Long termThis is a structural transformation that could re-rate the company from a formulations-heavy player to a diversified pharma entity with a scaled API platform.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of the Actis Generics acquisition
- Regulatory approvals for the slump sale
- Execution risk in scaling the API business to justify the ₹700 crore investment
Key Highlights
Initial investment of up to ₹243 crore from InvAscent funds into the new API subsidiary
Total investment roadmap of up to ₹700 crore in RPG Active Pharma to be deployed in tranches
100% acquisition of Actis Generics Private Limited to expand manufacturing infrastructure
The ₹700 crore investment plan is approximately 99% of the company's TTM revenue of ₹708 crore
API business transfer to be executed on a slump sale basis as a going concern
👀 What to Watch
Monitor the regulatory approval timeline for the slump sale and the specific acquisition cost for Actis Generics. Investors should track how the capital infusion impacts the consolidated debt-to-equity ratio and future margin profiles as the API business scales.
Rs 700 Cr Commitment for API Business via Subsidiary Restructuring and Acquisition
RPG Life Sciences is carving out its API business into a wholly-owned subsidiary, RPG Active Pharma Limited (RPGAP), via a slump sale for Rs 33.55 cr. Two private equity funds, India Life Sciences Fund IV and Vistaject Fund, will invest Rs 243.33 cr for a 40% stake in RPGAP, valuing the subsidiary at approximately Rs 608 cr. The parties have committed a total of up to Rs 700 cr for organic and inorganic growth in the API segment. Additionally, RPGAP is acquiring Actis Generics for Rs 80 cr to strengthen its intermediates supply chain.
Confidence: HIGH
What changedThe API business is being transitioned from an internal division to a well-funded subsidiary with 40% external PE ownership and a fresh acquisition (Actis Generics).
Why it mattersThis restructuring unlocks value in the API segment and provides significant growth capital (Rs 700 cr) without straining the parent company's balance sheet, allowing for aggressive inorganic expansion.
Total Growth Commitment: Rs 700 crPE Investment for 40% stake: Rs 243.33 crActis Acquisition Price: Rs 80 crAPI Revenue (FY26): Rs 95.06 crCommitment vs TTM Revenue: ~98.8%
📅 Short termThe market is likely to react positively to the valuation benchmark set by the PE investment and the clear growth roadmap for the API business.
📈 Long termThis represents a structural shift towards becoming a more significant player in the API and intermediates space, diversifying away from pure formulations.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in scaling the new subsidiary
- Integration risk of Actis Generics
- 40% dilution of ownership in the API business
Key Highlights
API business contributed Rs 95.06 cr (13.54% of total revenue) and Rs 70.92 cr (11.72% of net worth) in FY26.
PE investors to infuse Rs 243.33 cr for a 40% stake in the new API subsidiary.
Total growth capital commitment of up to Rs 700 cr, representing ~99% of the company's TTM revenue.
Acquisition of Actis Generics for Rs 80 cr, a firm with FY25 turnover of Rs 48.25 cr.
Slump sale expected to be completed by September 30, 2026; acquisition by November 15, 2026.
👀 What to Watch
Watch for the successful completion of the slump sale by September 2026 and the subsequent utilization of the Rs 700 cr commitment for further acquisitions or capacity expansion.
₹700 Cr API Growth Plan: RPGLIFE Restructures API Business with PE Funding and ₹80 Cr Acquisition
RPG Life Sciences is carving out its API business into a subsidiary, RPG Active Pharma (RPGAP), which contributed 13.54% (₹95.06 Cr) to FY26 revenue. PE investors (India Life Sciences Fund IV and Vistaject Fund) are infusing an initial ₹243.33 Cr for a 40% stake, with a total commitment of up to ₹700 Cr for growth. Simultaneously, the subsidiary is acquiring Actis Generics for ₹80 Cr to strengthen its supply chain in complex intermediates. This restructuring aims to provide strategic focus and capital for the API segment while the parent company focuses on formulations.
Confidence: HIGH
What changedThe API division is being hived off into a separate subsidiary with 40% external PE ownership and a massive capital commitment for expansion.
Why it mattersThis move unlocks value and provides dedicated capital for the API business without diluting the parent company's equity. The ₹700 Cr commitment is highly material compared to the company's current net worth of ₹605 Cr.
API Revenue (FY26): ₹95.06 CrInitial PE Investment: ₹243.33 CrTotal Growth Commitment: ₹700 CrActis Acquisition Cost: ₹80 CrCommitment vs Net Worth: 115.7%
📅 Short termThe market is likely to react positively to the large capital infusion and the strategic clarity provided by the carve-out and acquisition.
📈 Long termThis structurally transforms RPGLIFE into a well-funded API player alongside its formulations business, potentially driving higher growth through the ₹700 Cr investment pipeline.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in scaling the new API subsidiary
- Integration risk of Actis Generics
- Profit dilution at the consolidated level due to 40% PE stake in the API unit
Key Highlights
API business being transferred via slump sale for ₹33.55 Cr; unit contributed 13.54% of FY26 revenue.
PE investors to infuse ₹243.33 Cr for a 40% stake in the new API subsidiary (RPGAP).
Total growth capital commitment of up to ₹700 Cr, which exceeds the company's current net worth of ₹605 Cr.
Acquisition of Actis Generics for ₹80 Cr, a company with FY25 turnover of ₹48.25 Cr.
Restructuring expected to be completed by September 30, 2026, and acquisition by November 15, 2026.
👀 What to Watch
Watch for the successful completion of the Actis acquisition by November 2026 and the subsequent deployment of the ₹700 Cr commitment for organic or inorganic API expansion.
Rs 700 Cr API Growth Plan: RPG Life Restructures API Unit, Raises Funds, and Acquires Actis
RPG Life Sciences is carving out its API business into a subsidiary, RPG Active Pharma (RPGAP), for a slump sale consideration of Rs 33.55 Cr. External investors (ILSF IV and Vistaject) are investing Rs 243.33 Cr for a ~40% stake in this subsidiary, with a total commitment of up to Rs 700 Cr for organic and inorganic growth. As a first step, RPGAP is acquiring Actis Generics for Rs 80 Cr to strengthen its intermediate supply chain. This move aims to scale the API segment, which currently contributes 13.54% to the company's total revenue.
Confidence: HIGH
What changedThe API business is being transitioned from an internal division to a well-funded subsidiary with external PE backing and a dedicated acquisition strategy.
Why it mattersThis unlocks value for the API segment and provides a massive growth runway (Rs 700 Cr commitment is ~99% of TTM revenue) without diluting the parent company's equity.
API Revenue (FY26): Rs 95.06 CrAPI % of Total Revenue: 13.54%External Investment in WOS: Rs 243.33 CrTotal Growth Commitment: Rs 700 CrActis Acquisition Cost: Rs 80 CrCommitment vs TTM Revenue: ~98.8%
📅 Short termThe market is likely to react positively to the high valuation implied by the PE investment and the clear roadmap for inorganic growth.
📈 Long termStructural transformation into a vertically integrated pharma player with a significantly larger API footprint; the Rs 700 Cr commitment suggests a multi-year scaling phase.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risk of Actis Generics
- Dilution of ownership in the high-growth API subsidiary to 60%
- Cyclicality of the API and intermediate markets
Key Highlights
API business (FY26 revenue: Rs 95.06 Cr) transferred to subsidiary RPGAP for Rs 33.55 Cr
External investors to infuse Rs 243.33 Cr for a ~40% stake in the API subsidiary
Total commitment of up to Rs 700 Cr by parties for API growth opportunities
Acquisition of Actis Generics for Rs 80 Cr, a supplier of complex intermediates for APIs like Sitagliptin
Actis Generics reported a turnover of Rs 48.25 Cr in FY25
👀 What to Watch
Monitor the completion of the Actis acquisition by November 15, 2026, and the subsequent deployment of the remaining committed capital for further API expansions.
17% PAT Growth in Q1 FY27; RPG Life Enters Top 50 Indian Pharma Rankings
RPG Life Sciences reported a robust Q1 FY27 with revenue growing 15.8% YoY to ₹195.7 Cr and PAT increasing 17.0% to ₹30.8 Cr. The company achieved a significant milestone by entering the 'Top 50 Pharma Companies' list in India, improving its rank from 62 in March 2025 to 50 in June 2026. Domestic formulations, the largest segment at 68.3% of sales, grew 14.8% YoY, while the API segment saw a 35.6% jump despite a fire incident in one manufacturing block. Management is actively evaluating M&A opportunities and focusing on scaling its immunosuppressant portfolio to ₹200+ Cr.
Confidence: HIGH
What changedThe company broke into the top 50 Indian pharma companies and maintained double-digit growth across all segments in Q1 FY27.
Why it mattersDemonstrates successful execution of the '5 Pillar' strategy in domestic formulations and highlights the company's ability to maintain healthy margins (24.5% EBITDA) while scaling.
Q1 Revenue: ₹195.7 CrQ1 PAT: ₹30.8 CrEBITDA Margin: 24.5%Revenue vs TTM Revenue: ~27.6%Capex since FY22: ₹185+ Cr
📅 Short termPositive sentiment is expected due to the 'Top 50' ranking milestone and strong double-digit growth across segments.
📈 Long termStructural growth is driven by a focus on chronic/specialty therapies and potential inorganic expansion through a defined M&A framework.
⚠ Risk flags
- Product concentration risk in domestic formulations
- Impact of fire incident on API manufacturing capacity
- Dependency on imported intermediates
Key Highlights
Revenue from operations grew 15.8% YoY to ₹195.7 Cr in Q1 FY27
PAT (excluding exceptional items) increased 17.0% YoY to ₹30.8 Cr
Domestic Formulations sales reached ₹132.5 Cr, contributing 68.3% of total revenue
Company rank in Indian Pharma Market (IPM) improved to 50 in June 2026 from 62 in March 2025
API segment grew 35.6% YoY to ₹26.6 Cr despite a fire incident in one manufacturing block
👀 What to Watch
Monitor the progress of the M&A evaluation and the scaling of the immunosuppressant portfolio toward the ₹200 Cr target. Watch for any lingering impact from the fire incident on API production in subsequent quarters.
15.8% Revenue Growth in Q1 FY27; RPG Life Enters Top 50 Indian Pharma Companies
RPG Life Sciences reported a strong start to FY27 with Q1 revenue growing 15.8% YoY to ₹195.7 Cr. EBITDA margins expanded by 40 bps to 24.5%, significantly higher than the TTM average of 20.8%, driven by operating discipline and strategic launches. The Domestic Formulations business grew at 14.8%, outpacing the Indian Pharma Market (IPM) growth of 11.6%. Notably, the company entered the Top 50 Indian Pharma Companies list in June 2026, marking a significant scale milestone.
Confidence: HIGH
What changedRPG Life Sciences has officially entered the Top 50 Indian Pharma Companies list and successfully restarted its API unit operations, leading to a 35.6% surge in that segment.
Why it mattersThe consistent outperformance of the domestic market and significant margin expansion indicate successful execution of the company's 'five pillars' growth strategy, particularly in chronic and specialty therapies.
Revenue (Q1 FY27): ₹195.7 CrEBITDA Margin: 24.5%API Segment Growth: 35.6%Domestic Growth vs Market: 14.8% vs 11.6%Q1 Revenue vs TTM Revenue: 27.6%
📅 Short termThe stock may react positively to the margin expansion and the milestone of entering the Top 50 pharma rankings, reflecting improved operational efficiency.
📈 Long termThe company is structurally shifting towards higher-margin specialty segments and scaling its API business, which supports its long-term 12% CAGR target.
⚠ Risk flags
- High product concentration risk in domestic formulations
- Dependency on imported intermediates for API production
Key Highlights
Revenue from operations increased 15.8% YoY to ₹195.7 Cr for the quarter ended June 30, 2026
EBITDA grew 17.9% YoY to ₹48.0 Cr, with margins improving to 24.5%
API business delivered a high growth of 35.6% as manufacturing units returned to full operations
Domestic Formulations outperformed the market with 14.8% growth vs 11.6% for the IPM
Key brand Naprosyn recorded 16% growth, supported by double-digit growth in Nephrology and Rheumatology baskets
👀 What to Watch
Watch for the sustainability of the 24.5% EBITDA margin in upcoming quarters and the execution of the international market expansion strategy mentioned by management.
RPG Life Sciences Q1 FY27: PAT up 17% YoY to ₹30.76 Cr on 15.8% Revenue Growth
RPG Life Sciences reported a strong start to FY27 with consolidated revenue growing 15.8% YoY to ₹195.69 Cr. Net profit for the quarter increased by 17% YoY to ₹30.76 Cr, compared to ₹26.29 Cr in the same period last year. The company maintained healthy profitability with a Profit Before Tax (PBT) margin of 21.2%. Additionally, the company is progressing with the transfer of its API division to a wholly-owned subsidiary, RPG Active Pharma Limited, which is pending final approvals.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing double-digit growth in both revenue and profit compared to the previous year's first quarter.
Why it mattersThe results confirm steady growth momentum in the core pharmaceutical business and demonstrate the company's ability to scale its domestic formulation and API segments profitably.
Consolidated Revenue (Q1 FY27): ₹195.69 CrConsolidated PAT (Q1 FY27): ₹30.76 CrYoY Revenue Growth: 15.8%YoY PAT Growth: 17.0%PBT Margin: 21.2%
📅 Short termThe stock may see positive sentiment in the short term due to healthy double-digit growth in earnings and stable margins.
📈 Long termThe structural move to hive off the API division and focus on chronic/specialty portfolios supports long-term value creation, provided execution remains consistent.
⚠ Risk flags
- High product concentration risk in domestic formulations
- Regulatory dependency for the API division transfer
- Exposure to government price controls (DPCO)
Key Highlights
Consolidated Revenue from Operations increased 15.8% YoY to ₹195.69 Cr from ₹168.92 Cr.
Net Profit (PAT) grew 17% YoY to ₹30.76 Cr, up from ₹26.29 Cr in Q1 FY26.
Earnings Per Share (EPS) for the quarter rose to ₹18.60 from ₹15.90 YoY.
Profit Before Tax (PBT) stood at ₹41.46 Cr, representing a margin of 21.2%.
The transfer of the API division to subsidiary RPG Active Pharma Limited is currently in progress.
👀 What to Watch
Monitor the execution timeline for the API division hive-off and its impact on segment-wise margins. Watch for the company's ability to maintain its 12% targeted growth rate in the domestic formulations market.
RPG Life Sciences Launches Naprosyn ES in India via Archerchem Partnership
RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to launch Naprosyn ES, the first Naproxen and Esomeprazole combination in India. RPG LS will exclusively market and distribute the product pan-India, leveraging its legacy Naprosyn brand, while Archerchem acts as the exclusive supplier. This launch targets the chronic pain management segment, specifically patients needing long-term NSAID therapy with gastro-protection. The move aligns with RPG's strategy to grow its chronic/specialty portfolio, where new products launched since FY19 already contribute ~25% of domestic formulation sales.
Confidence: HIGH
What changedRPG Life Sciences has expanded its pain management portfolio by launching a first-in-India combination drug through an exclusive partnership with Archerchem Healthcare.
Why it mattersThe launch strengthens RPG's legacy Naprosyn brand and increases its presence in the chronic therapy segment, which is less volatile than acute segments and supports the company's 20.8% operating margins.
New product contribution to domestic sales: ~25%TTM Revenue: Rs 708 CrOperating Profit Margin: 20.8%Market Cap: Rs 4584 CrExpected Growth Rate: 12%
📅 Short termThe launch is likely to be viewed positively by the market as it demonstrates execution of the company's 'Product Portfolio Rejuvenation' strategy.
📈 Long termStructural shift towards chronic therapies and differentiated products could improve pricing power and reduce the impact of government price controls over time.
⚠ Risk flags
- Product concentration risk (high reliance on top brands)
- Dependency on Archerchem as the exclusive supplier
Key Highlights
First-time launch of Naproxen and Esomeprazole combination in the Indian pharmaceutical market.
RPG Life Sciences to serve as the exclusive marketing and distribution partner across India.
New products launched since FY19 now contribute approximately 25% of total domestic formulation sales.
Targets a TTM revenue base of Rs 708 Cr with a focus on high-margin chronic therapy segments.
Leverages a distribution network that includes super-specialists to drive adoption of the differentiated formulation.
👀 What to Watch
Monitor the domestic formulation growth in upcoming quarterly results to gauge the market uptake of Naprosyn ES and its contribution to the 12% targeted growth rate.
RPG Life Sciences Sets July 9 as Record Date for Rs 24 Final Dividend (300%)
RPG Life Sciences has fixed July 9, 2026, as the record date to determine shareholder eligibility for a final dividend of Rs 24 per share for FY 2025-26. This dividend represents a 300% payout on the face value of Rs 8 per share. The payout is subject to shareholder approval at the company's 19th Annual General Meeting scheduled for July 23, 2026. Once approved, the dividend will be credited to eligible shareholders within 30 days.
Key Highlights
Final dividend recommended at Rs 24 per equity share of Rs 8 face value (300%).
Record date for determining dividend eligibility is fixed as Thursday, July 9, 2026.
The 19th Annual General Meeting (AGM) is scheduled for Thursday, July 23, 2026.
Dividend payment will be processed within 30 days of approval at the ensuing AGM.
The board had initially recommended this dividend during its meeting on April 29, 2026.
👀 What to Watch
Investors looking to qualify for the Rs 24 dividend should ensure they purchase or hold the stock before the ex-dividend date, which is typically one working day prior to the July 9 record date.
RPG Life Sciences Reports FY26 Revenue of ₹707.5 Cr with Robust 24.4% EBITDA Margin
RPG Life Sciences delivered a strong performance in FY26, with revenue reaching ₹707.5 crore, an 8.3% growth over the previous year. The Domestic Formulations business, which contributes 69% of sales, outperformed the Indian Pharma Market (IPM) by 1.6x, leading to an improved market rank of 52nd. The company maintains high capital efficiency with a ROCE of 28.5% and a healthy cash reserve of ₹276.5 crore. Strategic focus remains on high-growth therapies like Nephrology and Oncology, alongside a volume-led growth strategy that significantly exceeded industry averages.
Key Highlights
FY26 Revenue grew to ₹707.5 Cr with a 5-year CAGR of 12.7%
Domestic Formulations business grew 1.6x faster than the Indian Pharma Market in FY26
Maintained strong profitability with an EBITDA margin of 24.4% and EPS of ₹69.6
Recorded robust volume growth of 6.4% compared to the IPM volume growth of 0.7%
Strong balance sheet with ₹276.5 Cr in cash reserves and a stable A+ credit rating
👀 What to Watch
Investors should note the company's consistent ability to outperform the broader pharmaceutical market and its high return ratios. The strong cash position and focus on specialty 'mega brands' suggest a sustainable growth trajectory for long-term portfolios.
RPG Life Sciences Recommends ₹24 Dividend and Appoints New Independent Director
RPG Life Sciences has recommended a final dividend of ₹24 per equity share (300% of face value) for the financial year ended March 31, 2026. The company also announced the appointment of Dr. Pratit Samdani, a renowned physician, as an Additional Non-Executive Independent Director for a five-year term. This announcement follows a regulatory filing to provide financial results in a machine-readable format, confirming that there are no changes to the previously reported audited figures. The board has confirmed unmodified audit opinions for both standalone and consolidated financial statements.
Key Highlights
Recommended a final dividend of ₹24 per equity share of face value ₹8 (300%) for FY 2025-26.
Appointed Dr. Pratit Samdani as Additional Non-Executive Independent Director from April 29, 2026, to April 28, 2031.
Audited financial results for Q4 and FY26 confirmed with an unmodified opinion from statutory auditors SR BC & CO LLP.
Resubmitted financial results in machine-readable/searchable form as per NSE request with zero changes to original data.
👀 What to Watch
Investors should track the upcoming Annual General Meeting for the final approval of the ₹24 dividend. The appointment of a medical expert to the board is a positive step for governance in a life sciences company.
RPG Life Sciences Q4 FY26: PAT Surges 58% YoY; Revenue Up 23.6% to ₹176.9 Cr
RPG Life Sciences delivered a robust performance in Q4 FY26, with revenue growing 23.6% YoY to ₹176.9 crore and PAT (excluding exceptional items) surging 58.1% to ₹29.3 crore. The company's domestic formulations business, which accounts for 69% of revenue, outperformed the Indian Pharmaceutical Market (IPM) by 1.6x for the full year. Despite a fire incident impacting the API segment's growth, the company maintained a debt-free status and significantly improved its EBITDA margins to 25.6% in Q4. Management is focusing on scaling core brands like Naprosyn and expanding its specialty and chronic portfolio to drive future growth.
Key Highlights
Q4 FY26 Revenue grew 23.6% YoY to ₹176.9 Cr, while EBITDA rose 48% to ₹45.2 Cr.
Domestic Formulations business grew 13.7% in FY26, outperforming the market and improving IPM rank from 58 to 52.
EBITDA margins expanded significantly in Q4 FY26 to 25.6% compared to 21.4% in Q4 FY25.
The company remains debt-free with a reaffirmed ICRA A+ (Stable) credit rating.
API segment growth was restricted to 5.3% in FY26 due to a fire incident in one of the manufacturing blocks.
👀 What to Watch
RPG Life Sciences is demonstrating strong operational leverage and market-beating growth in its domestic business. Investors should maintain a positive outlook given the debt-free balance sheet and the company's successful pivot toward high-margin specialty therapies.
RPG Life Sciences Recommends ₹24 Dividend and Appoints Dr. Pratit Samdani as Director
RPG Life Sciences has recommended a substantial final dividend of ₹24 per equity share (300% of face value) for FY 2025-26, pending shareholder approval. The company reported its audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from statutory auditors. In a strategic move, the board appointed Dr. Pratit Samdani, a highly respected physician, as an Additional Non-Executive Independent Director for a five-year term. The company also updated its internal code for fair disclosure and insider trading monitoring.
Key Highlights
Recommended a dividend of ₹24 per equity share of face value ₹8, representing a 300% payout.
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Appointed Dr. Pratit Samdani as an Independent Director for a 5-year term until April 2031.
Statutory auditors issued a report with an unmodified opinion on the company's financial statements.
Amended the Code of Fair Disclosure and internal procedures for regulating trading by designated persons.
👀 What to Watch
Investors should benefit from the significant dividend payout and may view the addition of a medical expert to the board as a positive for the company's long-term strategic growth in the pharma sector. Maintain a watch on the upcoming AGM for the final dividend approval and payment timeline.
RPG Life Sciences Recommends Rs 24 Dividend; Sets June 19 as Record Date
RPG Life Sciences has recommended a final dividend of Rs. 24 per equity share for FY 2025-26, which represents a 300% payout on the face value of Rs. 8. The company has fixed June 19, 2026, as the record date for determining shareholder eligibility for this dividend, pending AGM approval. Alongside the financial results, the board also appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for a five-year term. The dividend is expected to be paid within 30 days of the Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs. 24 per equity share (300% of face value)
Fixed June 19, 2026, as the record date for dividend entitlement
Approved audited standalone and consolidated financial results for FY 2025-26
Appointed Dr. Pratit Samdani as Independent Director for a 5-year term until 2031
Dividend payment to be completed within 30 days of shareholder approval at the AGM
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock prior to the record date of June 19, 2026. The 300% dividend payout indicates a strong commitment to returning capital to shareholders.
